Universitäts Klinikum Frankfurt
Welcome,         Profile    Billing    Logout  
 2 Trials 
7 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Goebell, Peter J
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
FOKAL-BT, NCT02391051: Focal Brachytherapy in Patients With Selected "Low-risk" Prostate Cancer - a Phase-II-trial

Recruiting
2
50
Europe
HDR-Brachytherapy
University of Erlangen-Nürnberg Medical School
Prostate Cancer
12/19
12/29
CARAT, NCT03374267: Registry Platform Urologic Cancer

Recruiting
N/A
1830
Europe
Routine care as per site standard.
iOMEDICO AG
Renal Cell Carcinoma, Urothelial Carcinoma
06/27
06/27
Banek, Severine
PREPARE, NCT03013946 / 2016-000399-28: Role of PRoactivE Coaching on PAtient REported Outcome in Advanced or Metastatic RCC Treated With Sunitinib or a Combination of Pembrolizumab + Axitinib or Avelumab + Axitinib in First Line Therapy

Recruiting
3
430
Europe
Concomitant coaching
AIO-Studien-gGmbH, Pfizer, Crolll Gmbh
Renal Cell Carcinoma, Metastatic, Renal Cell Cancer, Recurrent
01/24
07/24
ARASAFE, NCT05676203: A Trial Comparing Docetaxel 75 mg/m2 (3w) Versus Docetaxel 50 mg/m2 (2w) in Combination With Darolutamide + ADT in mHSPC Patients

Recruiting
3
250
Europe
Standard ADT (androgen deprivation therapy), Standard Darolutamide, Docetaxel
Jena University Hospital, Bayer
Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)
07/25
01/27
CYCLONE 3, NCT05288166: A Study of Abemaciclib (LY2835219) With Abiraterone in Men With Prostate Cancer That Has Spread to Other Parts of the Body and is Expected to Respond to Hormonal Treatment (Metastatic Hormone-Sensitive Prostate Cancer)

Active, not recruiting
3
900
Europe, Canada, Japan, US, RoW
Abemaciclib, LY2835219, Abiraterone, Prednisone or Prednisolone, Placebo for Abemaciclib
Eli Lilly and Company
Prostatic Neoplasms, Neoplasm Metastasis, Urogenital Neoplasms, Physiological Effects of Drugs, Antineoplastic Agents, Antineoplastic Agents, Hormonal, Androgens, Hormones, Hormones, Hormone Substitutes, and Hormone Antagonists, Abiraterone Acetate, Steroid Synthesis Inhibitors, Cytochrome P-450, Enzyme Inhibitors, Prednisone, Prednisolone, Cyclin-Dependent Kinase 4, Cyclin-Dependent Kinase 6
02/24
10/27
JAVELIN Bladder Medley, NCT05327530: A Study of the Safety and Efficacy of Various Combinations of Avelumab as Therapy in Locally Advanced or Metastatic Urothelial Carcinoma

Active, not recruiting
2
256
Europe, Canada, US, RoW
Avelumab, MSB0010718C, Sacituzumab Govitecan, IMMU-132, Trodelvy™, GS-0132, M6223, NKTR-255
EMD Serono Research & Development Institute, Inc., Merck KGaA, Darmstadt, Germany; Gilead Sciences; Nektar Therapeutics
Locally Advanced or Metastatic Urothelial Carcinoma
01/25
01/25

Download Options